What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis?

Franck Thuny; Marc P Bonaca; Jennifer Cautela

doi:10.1016/j.jaccao.2022.06.008

What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis?

JACC CardioOncol. 2022 Dec 20;4(5):624-628. doi: 10.1016/j.jaccao.2022.06.008. eCollection 2022 Dec.

Authors

Franck Thuny^{1

2

3}, Marc P Bonaca⁴, Jennifer Cautela^{1

2

3}

Affiliations

¹ Aix-Marseille University, University Mediterranean Center of Cardio-Oncology, Department of Cardiology, Assistance Publique-Hôpitaux de Marseille, North Hospital, Marseille, France.
² Center for CardioVascular and Nutrition Research (C2VN), Inserm 1263, Inrae 1260, Marseille, France.
³ French Working Group of Cardio-Oncology, France.
⁴ Colorado Prevention Centre, Clinical Research, University of Colorado School of Medicine, Aurora, Colorado, USA.

No abstract available

Keywords: 2018-LL, 2018-Lake Louise; ACS, acute coronary syndrome; CMR, cardiac magnetic resonance; ECG, electrocardiogram; EMB, endomyocardial biopsy; IC-OS, International Cardio-Oncology Society; ICI, immune checkpoint inhibitor; ICI-M, immune checkpoint inhibitor–induced myocarditis; LGE, late gadolinium enhancement; MACE, major cardiovascular events; cTn, cardiac troponin; diagnosis; immunotherapy; irAE, immune-related adverse event; myocarditis; screening.

Publication types

Review